DUBLIN–(BUSINESS WIRE)–The “Multiple Sclerosis Drugs Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 – 2027” report has been added to ResearchAndMarkets.com’s offering.
Multiple Sclerosis Drugs Market – Scope of the Report
This report on the multiple sclerosis drugs market studies the past as well as the current growth trends and opportunities, to gain valuable insights of the same indicators for the market over the forecast period from 2019 to 2027. The report provides the overall market revenue of the multiple sclerosis drugs market for the period 2017-2027, considering 2018 as the base year and 2027 as the forecast year. The report also provides the compound annual growth rate (CAGR) of the multiple sclerosis drugs market for the forecast period 2019-2027.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the multiple sclerosis drugs market. These indices serve as valuable tools for existing market players as well as for entities interested in participating in the multiple sclerosis drugs market.
The report also delves into the competitive landscape of the multiple sclerosis drugs market. Key players operating in the multiple sclerosis drugs market have been identified and each one of these has been profiled for distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players in the multiple sclerosis drugs market that have been profiled in this report.
Key Questions Answered
- How does the development of multiple sclerosis drugs provide the scope of growth in the multiple sclerosis drugs market?
- How alliances and partnerships between players are widening the scope of new line of treatment for multiple sclerosis?
- What are the revenue share projections of key segments under various criteria in the multiple sclerosis drugs market during the forecast period?
- Which segment is likely to register leading revenue until the end of the forecast period in 2027?
- How is the evolving healthcare system in developing countries of Asia Pacific making an impact on the overall multiple sclerosis drugs market?
Key Topics Covered:
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Multiple Sclerosis Drugs Market
4. Market Overview
4.1. Introduction
4.2. Overview
4.3. Market Dynamics
4.4. Global Multiple Sclerosis Drugs Market Analysis and Forecast, 2017-2027
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Pipeline Analysis
5.2. Regulatory Scenario
5.3. Disease Epidemiology
5.4. Market Access Overview
5.5. Key Mergers & Acquisitions
6. Global Multiple Sclerosis Drugs Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Drug Class, 2017-2027
6.4. Market Attractiveness, by Drug Class
7. Global Multiple Sclerosis Drugs Market Analysis and Forecast, by Disease Type
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Disease Type, 2017-2027
7.4. Market Attractiveness, by Disease Type
8. Global Multiple Sclerosis Drugs Market Analysis and Forecast, by Route of Administration
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Route of Administration, 2017-2027
8.4. Market Attractiveness by Route of Administration
9. Global Multiple Sclerosis Drugs Market Analysis and Forecast, by Distribution Channel
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by Distribution Channel, 2017-2027
9.4. Market Attractiveness, by Distribution Channel
10. Global Multiple Sclerosis Drugs Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region
10.3. Market Attractiveness, by Country/Region
11. North America Multiple Sclerosis Drugs Market Analysis and Forecast
11.1. Introduction
11.2. Market Value Forecast, by Drug Class, 2017-2027
11.3. Market Value Forecast, by Disease Type, 2017-2027
11.4. Market Value Forecast, by Route of Administration, 2017-2027
11.5. Market Value Forecast, by Distribution Channel, 2017-2027
11.6. Market Value Forecast, by Country, 2017-2027
11.7. Market Attractiveness Analysis
12. Europe Multiple Sclerosis Drugs Market Analysis and Forecast
13. Asia Pacific Multiple Sclerosis Drugs Market Analysis and Forecast
14. Latin America Multiple Sclerosis Drugs Market Analysis and Forecast
15. Middle East & Africa Multiple Sclerosis Drugs Market Analysis and Forecast
16. Competition Landscape
16.1. Market Share Analysis, by Company, 2018
16.2. Company Profiles
16.2.1. Bayer AG
16.2.2. Teva Pharmaceutical Industries Ltd.
16.2.3. Novartis AG
16.2.4. Sanofi
16.2.5. F. Hoffmann-La Roche Ltd.
16.2.6. Celgene Corporation
16.2.7. Acorda Therapeutics, Inc.
16.2.8. Biogen, Inc.
16.2.9. Actelion Pharmaceuticals
16.2.10. EMD Serono
16.2.11. AbbVie, Inc.
For more information about this report visit https://www.researchandmarkets.com/r/tv6148
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900